Phentermine is contraindicated during breastfeeding
A breastfeeding patient should NOT take phentermine. The FDA drug label explicitly states that while it is unknown if phentermine is excreted in human milk, other amphetamines are present in breast milk, and "because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug" 1.
Key Evidence
FDA Drug Label (Highest Priority)
The official phentermine prescribing information clearly addresses this scenario 1:
- Unknown excretion in human milk, but related amphetamines ARE present in breast milk
- Risk of serious adverse reactions in nursing infants
- Must choose between discontinuing breastfeeding OR discontinuing the medication
Supporting Guideline Evidence
Multiple recent obesity management guidelines consistently list pregnancy and breastfeeding as absolute contraindications to phentermine use:
- The 2023 South/Southeast Asia obesity consensus explicitly contraindicates phentermine in breastfeeding 2
- The 2025 AACE consensus algorithm states "all medications are contraindicated in pregnancy and breastfeeding" when discussing phentermine 3
- The 2019 RCOG guideline on obesity in pregnancy notes that phentermine/topiramate is "not recommended during lactation due to unknown risks on the infant" 4
Mechanism of Concern
Phentermine is a sympathomimetic amine structurally and pharmacologically related to amphetamines 1. The concern stems from:
- Amphetamines are known to transfer into breast milk
- Potential for infant exposure to stimulant effects
- Risk of irritability, insomnia, and feeding difficulties in the infant 5
Clinical Implications
If weight management is needed during breastfeeding:
- Prioritize lifestyle modifications (diet and exercise counseling)
- Delay pharmacotherapy until after weaning
- Consider alternative non-pharmacologic interventions
If the patient is already taking phentermine and wishes to breastfeed:
- Discontinue phentermine before initiating breastfeeding
- Allow adequate washout period (phentermine half-life considerations)
- Implement comprehensive lifestyle interventions as alternative
Important Caveats
The evidence base is limited—there are no published studies specifically examining phentermine levels in breast milk or infant outcomes 1. However, the precautionary principle applies: given phentermine's amphetamine-like structure and the known presence of amphetamines in breast milk, the risk-benefit analysis clearly favors avoiding use during lactation.
The 2024 ADHD guideline provides relevant context for amphetamine-class medications during breastfeeding, noting that while therapeutic amphetamine use may be compatible with careful monitoring for irritability and feeding problems 5, this applies to medically necessary ADHD treatment—not elective weight loss medication where safer alternatives exist.